Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10375203 | 0.98 | HIF1A (0.54) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL286655 | 0.94 | HIF1A (0.58) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL28039442 | 0.89 | HIF1A (0.58) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL2446042 | 0.87 | HIF1A (0.74) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL10842501 | 0.86 | HIF1A (0.50) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL164818 | 0.85 | HIF1A (0.71) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL4184421 | 0.84 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL8761335 | 0.84 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL2450121 | 0.84 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL52420 | 0.84 | HIF1A (0.70) | HIF1AALDH1A1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575136-B2 | 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2021321-B1 | 2-METHYLENE-1ALPHA,25-DIHYDROXY-18,19,21-TRINORVITAMIN D3 AND USES THEREOF | WISCONSIN ALUMNI RES FOUND (US) | 2012-06-20 | — | — | EP | disclosed |
| EP-2001841-B1 | 2-METHYLENE-1 ALPHA-HYDROXY-18,19,21-TRINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RES FOUND (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2001842-B1 | 2-METHYLENE-1ALPHA-HYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RES FOUND (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2046737-B1 | 2-METHYLENE-1 ALPHA,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RES FOUND (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7704981-B2 | 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-7648973-B2 | 2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648972-B2 | 2-methylene-1α-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-19 | — | — | US | disclosed |
| EP-2046737-A2 | 2-METHYLENE-1 ALPHA,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-2021321-A2 | 2-METHYLENE-1ALPHA,25-DIHYDROXY-18,19,21-TRINORVITAMIN D3 AND USES THEREOF | Wisconsin Alumni Research Foundation (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-2001841-A2 | 2-METHYLENE-1 ALPHA-HYDROXY-18,19,21-TRINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-2001842-A2 | 2-METHYLENE-1ALPHA-HYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008125901-A2 | 2-METHYLENE-1ALPHA,25-DIHYDROXY-18,19,21-TRINORVITAMIN D3 AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008035207-A2 | 2-METHYLENE-1ALPHA-HYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008035206-A2 | 2-METHYLENE-1 ALPHA-HYDROXY-18,19,21-TRINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007118198-A2 | 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238705-A1 | 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
| US-20070238702-A1 | 2-Methylene-1Alpha-Hydroxy-19,21-Dinorvitamin D3 Analogs and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
| US-20070238701-A1 | 2-Methylene-1alpha-Hydroxy-18,19,21-Trinorvitamin D3 Analogs and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
| US-20070238706-A1 | Metabolic bone disease; psoriasis; leukemia; colon, breast, prostate, skin, lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, psoriasis | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238702-A1 | 2-Methylene-1Alpha-Hydroxy-19,21-Dinorvitamin D3 Analogs and Uses Thereof | CYP24A1, CYP27B1, CYP2R1 | HIF1A 253/4885ALDH1A1 394/4885CYP1A2 147/4885 |
| US-20070238706-A1 | Metabolic bone disease; psoriasis; leukemia; colon, breast, prostate, skin, lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, psoriasis | SHBG, HLA-DRB1, BRCA1 | HIF1A 105/4885ALDH1A1 1329/4885CYP1A2 162/4885 |
| US-20070238701-A1 | 2-Methylene-1alpha-Hydroxy-18,19,21-Trinorvitamin D3 Analogs and Uses Thereof | CYP24A1, CYP27B1, CYP2R1 | HIF1A 243/4885ALDH1A1 500/4885CYP1A2 93/4885 |
| US-20070238705-A1 | 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof | CYP24A1, CYP27B1, CYP2R1 | HIF1A 264/4885ALDH1A1 701/4885CYP1A2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.